Target intelligence / Profile preview

Cystic fibrosis transmembrane conductance regulator (CFTR) exon 23 5' splice site (CFTR exon 23 5'ss)

Target
CFTR exon 23 5'ss
Molecular classification
RNA, Pre-mRNA, Splice site, Other
01

Overview

The CFTR exon 23 5' splice site is a specific sequence in the pre-mRNA of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that defines the boundary between exon 23 and the following intron (SpliSense, 2023). This site is a primary therapeutic target for antisense oligonucleotides (ASOs) aimed at treating Cystic Fibrosis patients with the W1282X nonsense mutation, which is located within exon 23 (Kim et al., 2022). By binding to this 5' splice site, ASOs can sterically block the splicing machinery, leading to the exclusion of exon 23 from the mature mRNA transcript (Michaels et al., 2022). Because exon 23 is 84 nucleotides long, its removal preserves the reading frame, allowing for the translation of a truncated but partially functional CFTR protein that lacks the mutation-bearing segment (Cystic Fibrosis Foundation, 2023). This "exon skipping" strategy is designed to restore chloride channel function in patients who do not benefit from existing CFTR modulators like ivacaftor or elexacaftor (SpliSense, 2023). Therapeutic development targeting this site, such as the candidate SPLS-1282, represents a precision medicine approach for rare or difficult-to-treat CF genotypes (SpliSense, 2023). The success of this approach depends on the efficient delivery of the ASO to the lung epithelium and the ability of the resulting Δ23-CFTR protein to traffic to the cell surface and facilitate ion transport (Kim et al., 2022).

Other names
CFTR exon 23 donor splice siteCFTR exon 26 5' splice siteCFTR pre-mRNA exon 23 5'ssCFTR c.3846G>A splice targetCFTR exon 23 5-prime splice site
02

Mechanism of action

Induction of exon skipping via steric hindrance of the splicing machinery to bypass nonsense mutations while maintaining the reading frame.

03

Biological functions

RNA splicingGene expression regulationOther
04

Disease associations

Cystic FibrosisOther
05

Safety considerations

Off-target effects on non-target pre-mRNAsPotential for reduced stability or activity of the truncated proteinDelivery challenges to the airway epitheliumInnate immune response to antisense oligonucleotides
06

Interacting drugs

SPLS-1282

1 more in the full profile.

07

Biomarkers

CFTR mRNA splicing patternSweat chloride concentrationNasal potential differenceForced expiratory volume in 1 second (FEV1)

Beyond the preview

Go deeper on Cystic fibrosis transmembrane conductance regulator (CFTR) exon 23 5' splice site (CFTR exon 23 5'ss).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cystic fibrosis transmembrane conductance regulator (CFTR) exon 23 5' splice site (CFTR exon 23 5'ss).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call